Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study.

Juan M Maza-SolanoChristian Calvo-HenríquezIsam AlobidMarta Álvarez-CendreroÓscar Palomares Ramon Moreno-Luna Jaime Santos-Perez Jaime González-García Serafín Sánchez-Gómez

Published in: Journal of clinical medicine (2022)

A significant clinical response based on SNOT-22 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT-22 questionnaires.

Keyphrases

end stage renal disease
newly diagnosed
chronic obstructive pulmonary disease
ejection fraction
lung function
combination therapy
peritoneal dialysis
depressive symptoms
monoclonal antibody